SYDNEY, Australia, Feb. 23, 2026 — Clarity Pharmaceuticals announced a significant clinical milestone in the ongoing SECuRE Trial, reporting that another participant with metastatic castration-resistant prostate cancer (mCRPC) achieved undetectable prostate-specific antigen (PSA) levels and a negative PSMA PET scan following treatment with investigational radiopharmaceutical 67Cu-SAR-bisPSMA. The patient demonstrated undetectable PSA after the first treatment cycle, with confirmatory imaging showing no detectable disease after the second cycle, reinforcing the therapy’s emerging efficacy and safety profile.
Science Significance
The latest SECuRE trial outcome underscores the scientific promise of targeted copper theranostics, a next-generation radiopharmaceutical approach combining diagnostic imaging and therapeutic delivery. The investigational agent 67Cu-SAR-bisPSMA leverages prostate-specific membrane antigen (PSMA) targeting to deliver cytotoxic radiation directly to cancer cells while sparing surrounding tissue. This dual diagnostic-therapeutic mechanism enhances lesion detection and treatment precision. The reported case marks the fifth participant to achieve radiographically undetectable disease, strengthening early efficacy signals. Notably, the patient — diagnosed 15 years prior and progressing to metastatic disease — demonstrated rapid biochemical response within seven weeks, highlighting the therapy’s potential in late-stage oncology intervention.
Regulatory Significance
From a regulatory perspective, the findings support continued advancement of the SECuRE study toward registrational development. The trial’s Phase I/IIa design evaluates safety, dosimetry, and therapeutic response, generating evidence required for future marketing submissions. Encouraging safety data — with only mild Grade 1 adverse events and no hematological or renal toxicity observed — reinforces regulatory confidence in the therapy’s tolerability. Ongoing recruitment and Phase III planning indicate alignment with regulatory pathways for radiopharmaceutical approvals, which require robust imaging, survival, and toxicity endpoints before commercialization authorization.
Business Significance
Advertisement
For Clarity Pharmaceuticals, the clinical update strengthens the commercial and strategic positioning of its SAR-bisPSMA theranostic platform. Positive interim outcomes enhance investor confidence, partnership prospects, and competitive differentiation in the expanding radiopharmaceutical oncology market. The company is concurrently advancing diagnostic and therapeutic copper-based isotopes, creating a vertically integrated precision oncology franchise. Continued efficacy validation supports future licensing, manufacturing scale-up, and global commercialization pathways across prostate cancer treatment settings.
Patients’ Significance
For patients with metastatic castration-resistant prostate cancer — a population with limited therapeutic options — the results offer meaningful hope. Achieving undetectable disease on both PSA biomarker testing and molecular imaging represents a profound clinical outcome, particularly in heavily pretreated individuals. The favorable safety profile further supports treatment tolerability, preserving quality of life during therapy. As additional patients demonstrate similar responses, theranostic radiopharmaceuticals may redefine late-stage prostate cancer care, offering targeted disease eradication where conventional therapies fall short.
Policy Significance
The advancement of copper-based theranostics aligns with broader healthcare policy priorities supporting precision oncology, radiopharmaceutical manufacturing capacity, and nuclear medicine infrastructure. Governments and regulators are increasingly investing in isotope supply chains, imaging facilities, and specialized treatment centers to support next-generation cancer therapies. Clinical progress in trials such as SECuRE reinforces the need for regulatory harmonization, reimbursement frameworks, and workforce readiness to enable equitable patient access to radioligand treatments.
The latest SECuRE trial update marks another pivotal step in validating 67Cu-SAR-bisPSMA as a transformative radiopharmaceutical therapy for advanced prostate cancer. With multiple patients now achieving undetectable disease and Phase III planning underway, Clarity Pharmaceuticals is advancing toward registrational development and potential commercialization. As targeted theranostics continue to reshape oncology treatment paradigms, sustained clinical success could position copper-based radiopharmaceuticals at the forefront of precision cancer care.
Source: Clarity Pharmaceuticals press release
